Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

4BIO Ventures II Fund

4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces 9 September 2019 that it has completed the first close of its second venture fund, 4BIO Ventures II. Over $50 million of capital has been committed from family offices and institutional investors. The Group is targeting $150 million for the final close by the second half of 2020. 4BIO Ventures II will invest in 8 to 12 private companies developing advanced therapies – such as cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome – in areas of high unmet need. The Group’s objective is to build, support and grow early stage companies with the ultimate goal of ensuring sustainable access to these potentially curative therapies for all patients. The fund will be focused solely on advanced therapies without geographic limit, giving investors undiluted access to the fastest growing field of medicine. *


Period Start 2019-09-09 closing, first
  Group 4BIO Ventures (4BIO Capital) (Group)
Products Industry venture capital
  Industry 2 LIFE SCIENCES
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 78 Pall Mall
  City SW1Y 5ES London
  Tel +44-203-427-5500
    Address record changed: 2020-12-02
Basic data Employees n. a.
  Currency USD
  Annual sales 50,000,000 (first closing (2019) 2019-09-09)
Record changed: 2021-02-21


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for 4BIO Ventures (4BIO Capital) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top